(firstQuint)Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis.

 This is a multi-center, randomized, double blind, placebo-controlled, single dose escalation study of the safety and tolerability of subcutaneously administered REGN88 in rheumatoid arthritis patients who are receiving concomitant methotrexate.

 Three (3) sequential dose cohorts of 5 subjects (4:1 active: placebo) will be dosed SC with REGN88 or placebo.

 Subjects who complete the study will participate in 14 study visits over 16 weeks.

.

 Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis@highlight

This study will test the safety and tolerability (how the body reacts to the drug) of REGN88 and placebo (an inactive substance that contains no medicine) in patients with Rheumatoid Arthritis.

